Safety and Efficacy of BAF312 in Dermatomyositis

NCT02029274 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated prematurely after an interim analysis for futility. The study did not provide any evidence for efficacy of BAF312 in dermatomyositis.

Conditions

Active Dermatomyositis

Interventions

DRUG: BAF312
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals